-$0.27 EPS Expected for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) This Quarter

Wall Street brokerages expect Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report earnings per share of ($0.27) for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Aclaris Therapeutics’ earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.37). Aclaris Therapeutics posted earnings of ($0.28) per share in the same quarter last year, which would suggest a positive year over year growth rate of 3.6%. The business is expected to report its next earnings results on Friday, August 6th.

On average, analysts expect that Aclaris Therapeutics will report full-year earnings of ($1.45) per share for the current year, with EPS estimates ranging from ($1.75) to ($1.22). For the next financial year, analysts forecast that the company will report earnings of ($1.32) per share, with EPS estimates ranging from ($1.45) to ($1.05). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Aclaris Therapeutics.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Thursday, May 6th. The biotechnology company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.27). The firm had revenue of $1.78 million for the quarter, compared to the consensus estimate of $1.47 million. Aclaris Therapeutics had a negative net margin of 936.71% and a negative return on equity of 107.60%.

Several equities analysts have recently commented on ACRS shares. Zacks Investment Research raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 13th. Piper Sandler began coverage on shares of Aclaris Therapeutics in a research report on Tuesday, June 15th. They set an “overweight” rating on the stock. Finally, HC Wainwright began coverage on shares of Aclaris Therapeutics in a research report on Wednesday, April 21st. They set a “buy” rating on the stock.

Shares of NASDAQ:ACRS traded down $0.02 during midday trading on Thursday, hitting $15.74. 4,356 shares of the stock traded hands, compared to its average volume of 903,643. The stock’s 50 day simple moving average is $18.95. The company has a current ratio of 9.27, a quick ratio of 9.27 and a debt-to-equity ratio of 0.10. Aclaris Therapeutics has a one year low of $1.82 and a one year high of $30.38.

In other Aclaris Therapeutics news, insider Kamil Ali-Jackson sold 15,000 shares of the company’s stock in a transaction dated Wednesday, May 5th. The shares were sold at an average price of $23.98, for a total value of $359,700.00. Following the sale, the insider now owns 158,618 shares in the company, valued at $3,803,659.64. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David N. Gordon sold 2,631 shares of the stock in a transaction that occurred on Tuesday, July 13th. The shares were sold at an average price of $16.98, for a total transaction of $44,674.38. Following the transaction, the insider now owns 147,447 shares in the company, valued at approximately $2,503,650.06. The disclosure for this sale can be found here. In the last 90 days, insiders sold 122,138 shares of company stock worth $2,856,286. Corporate insiders own 8.20% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada grew its stake in Aclaris Therapeutics by 85.6% during the first quarter. Royal Bank of Canada now owns 3,515 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 1,621 shares in the last quarter. Dorsey Wright & Associates lifted its holdings in shares of Aclaris Therapeutics by 135.0% in the 1st quarter. Dorsey Wright & Associates now owns 6,110 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 3,510 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Aclaris Therapeutics in the 1st quarter worth about $204,000. Squarepoint Ops LLC bought a new stake in shares of Aclaris Therapeutics in the 1st quarter worth about $215,000. Finally, Diametric Capital LP bought a new stake in shares of Aclaris Therapeutics in the 1st quarter worth about $278,000. 87.15% of the stock is owned by institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation.

See Also: What are the Benefits of Index Funds?

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.